Table 1 Structural variant (SV) frequency by tumor BRCA2 alteration status for primary and metastatic prostate tumors in GENIE and TCGA.
From: The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer
| Â | Â | Primary tumors | Metastatic tumors | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
SV Type | SV Presence | n BRCA2d | % | n BRCA2i | % | P-value | n BRCA2d | % | n BRCA2i | % | P-valuea |
TMPRSS2-ETS | Present | 22 | 32.8% | 533 | 31.1% | 0.78 | 17 | 25.0% | 220 | 27.2% | 0.78 |
Absent | 45 | 67.2% | 1181 | 68.9% | 51 | 75.0% | 588 | 72.8% | |||
ETS-Other | Present | 0 | 0.0% | 28 | 1.5% | 0.62 | 0 | 0.0% | 3 | 0.4% | 1.00 |
Absent | 70 | 100.0% | 1853 | 99.8% | 68 | 100.0% | 805 | 99.6% | |||
TMPRSS2-ERG | Present | 19 | 28.4% | 513 | 29.9% | 0.89 | 15 | 22.1% | 212 | 26.4% | 0.48 |
Absent | 48 | 71.6% | 1201 | 70.1% | 53 | 77.9% | 592 | 73.6% | |||
TMPRSS2-ETV1 | Present | 1 | 1.5% | 4 | 0.2% | 0.17 | 2 | 3.0% | 1 | 0.1% | 0.017 |
Absent | 66 | 98.5% | 1708 | 99.8% | 65 | 97.0% | 803 | 99.9% | |||
TMPRSS2-intragenic | Present | 2 | 3.0% | 32 | 1.9% | 0.37 | 1 | 1.5% | 23 | 2.9% | 1.00 |
Absent | 65 | 97.0% | 1682 | 98.1% | 67 | 98.5% | 781 | 97.1% | |||
